Drug–drug interaction study of imatinib and voriconazole in vitro and in vivo

References

• van Leeuwen RW, van Gelder T, Mathijssen RH, Jansman FG. Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective. Lancet Oncol. 2014;15(8):e315–e326. doi:10.1016/S1470-2045(13)70579-524988935
   PubMed Web of Science ®Google Scholar
• Dookeeram D, Bidaisee S, Paul JF, et al. Polypharmacy and potential drug-drug interactions in emergency department patients in the Caribbean. Int J Clin Pharm. 2017;39(5):1119–1127. doi:10.1007/s11096-017-0520-928795285
   PubMed Web of Science ®Google Scholar
• Rodrigues MCS, de Oliveira C. Drug-drug interactions and adverse drug reactions in polypharmacy among older adults: an integrative review. Rev Lat Am Enfermagem. 2016;24: e2800.
   Web of Science ®Google Scholar
• Gu H, Dutreix C, Rebello S, et al. Simultaneous physiologically based pharmacokinetic (PBPK) modeling of parent and active metabolites to investigate complex CYP3A4 drug-drug interaction potential: a case example of midostaurin. Drug Metab Dispos. 2018;46(2):109–121. doi:10.1124/dmd.117.07800629117990
   PubMed Web of Science ®Google Scholar
• Luo M, Dai MY, Lin HT, et al. Species-related exposure of phase II metabolite gemfibrozil 1-O–glucuronide between human and mice: a net induction of mouse P450 activity was revealed. Biopharm Drug Dispos. 2017;38(9):535–542. doi:10.1002/bdd.210528946176
   PubMed Web of Science ®Google Scholar
• Groll AH, Castagnola E, Cesaro S, et al. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol. 2014;15(8):e327–e340. doi:10.1016/S1470-2045(13)70510-224988936
   PubMed Web of Science ®Google Scholar
• Solano C, Slavin M, Shaul AJ, et al. Economic evaluation of azoles as primary prophylaxis for the prevention of invasive fungal infections in Spanish patients undergoing allogeneic haematopoietic stem cell transplant. Mycoses. 2017;60(2):79–88. doi:10.1111/myc.1255227562016
   PubMed Web of Science ®Google Scholar
• Alanio A, Denis B, Hamane S, et al. Azole resistance of aspergillus fumigatus in immunocompromised patients with invasive aspergillosis. Emerg Infect Dis. 2016;22(1):157–158. doi:10.3201/eid2201.15084826690934
   PubMed Web of Science ®Google Scholar
• Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother. 2011;55(10):4782–4788. doi:10.1128/AAC.01083-1021768513
   PubMed Web of Science ®Google Scholar
• Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos. 2003;31(5):540–547.12695341
   PubMed Web of Science ®Google Scholar
• Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis. 2008;46(2):201–211. doi:10.1086/52466918171251
   PubMed Web of Science ®Google Scholar
• Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2012 Update on diagnosis, monitoring, and management. Am J Hematol. 2012;87(11):1038–1045. doi:10.1002/ajh.23282
   Web of Science ®Google Scholar
• Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–884. doi:10.1182/blood-2013-05-50156923803709
   PubMed Web of Science ®Google Scholar
• Manley PW, Blasco F, Mestan J, Aichholz R. The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588. Bioorg Med Chem. 2013;21(11):3231–3239. doi:10.1016/j.bmc.2013.03.03823611771
   PubMed Web of Science ®Google Scholar
• Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879–894. doi:10.2165/00003088-200544090-0000116122278
   PubMed Web of Science ®Google Scholar
• Herbrink M, Nuijen B, Schellens JHM, Beijnen JH. Variability in bioavailability of small molecular tyrosine kinase inhibitors. Cancer Treat Rev. 2015;41(5):412–422. doi:10.1016/j.ctrv.2015.03.00525818541
   PubMed Web of Science ®Google Scholar
• Hachem R, Gomes MZ, El Helou G, et al. Invasive aspergillosis caused by Aspergillus terreus: an emerging opportunistic infection with poor outcome independent of azole therapy. J Antimicrob Chemother. 2014;69(11):3148–3155. doi:10.1093/jac/dku24125006241
   PubMed Web of Science ®Google Scholar
• Lin G, Wang C, Qiu X, et al. Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat. Drug Dev Ind Pharm. 2014;40(12):1616–1622.24053419
   PubMed Web of Science ®Google Scholar
• Luo X, Li T, Yu Z, et al. The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes. Xenobiotica. 2018;1–18.
   PubMed Web of Science ®Google Scholar
• O‘Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer. 2003;89(10):1855–1859. doi:10.1038/sj.bjc.660115214612892
   PubMed Web of Science ®Google Scholar
• Xu RA, Lin Q, Qiu X, et al. UPLC-MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma. J Pharm Biomed Anal. 2019;166:6–12. doi:10.1016/j.jpba.2018.12.03630594035
   PubMed Web of Science ®Google Scholar
• Wang Z, Sun W, Huang CK, et al. Inhibitory effects of curcumin on activity of cytochrome P450 2C9 enzyme in human and 2C11 in rat liver microsomes. Drug Dev Ind Pharm. 2015;41(4):613–616. doi:10.3109/03639045.2014.88669724517573
   PubMed Web of Science ®Google Scholar
• Beumer JH, Pillai VC, Parise RA, et al. Human hepatocyte assessment of imatinib drug-drug interactions – complexities in clinical translation. Br J Clin Pharmacol. 2015;80(5):1097–1108. doi:10.1111/bcp.1272326178713
   PubMed Web of Science ®Google Scholar
• Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol. 2004;54(4):290–294. doi:10.1007/s00280-004-0832-z15138710
   PubMed Web of Science ®Google Scholar
• Gambillara E, Laffitte E, Widmer N, et al. Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia. Dermatology. 2005;211(4):363–365. doi:10.1159/00008851016286749
   PubMed Web of Science ®Google Scholar
• van Erp NP, Gelderblom H, Karlsson MO, et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res. 2007;13(24):7394–7400. doi:10.1158/1078-0432.CCR-07-034618094422
   PubMed Web of Science ®Google Scholar
• Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997;283(2):434–442.9353355
   PubMed Web of Science ®Google Scholar
• Mikus G, Schowel V, Drzewinska M, et al. Potent cytochrome P4502C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir. Clin Pharmacol Ther. 2006;80(2):126–135. doi:10.1016/j.clpt.2006.04.00416890574
   PubMed Web of Science ®Google Scholar
• Murayama N, Imai N, Nakane T, Shimizu M, Yamazaki H. Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem Pharmacol. 2007;73(12):2020–2026. doi:10.1016/j.bcp.2007.03.01217433262
   PubMed Web of Science ®Google Scholar
• Filppula AM, Laitila J, Neuvonen PJ, Backman JT. Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012;165(8):2787–2798. doi:10.1111/j.1476-5381.2011.01732.x22014153
   PubMed Web of Science ®Google Scholar